KURA - Kura Oncology doses first patient in mid-stage tipifarnib + alpelisib study in head/neck cancer

Kura Oncology (KURA +0.8%) announces dose administration for the first patient in Phase 1/2 KURRENT clinical trial of tipifarnib in combination with Novartis’ alpelisib in patients with head and neck squamous cell carcinoma (HNSCC). The KURRENT trial is a biomarker-defined cohort study designed to evaluate the safety, determine the recommended combination dosing and assess early anti-tumor activity of tipifarnib and alpelisib for the treatment of HNSCC patients whose tumors are dependent on HRAS and/or PI3K? pathways. Earlier this year, Kura collaborated with Novartis to evaluate tipifarnib and alpelisib in HNSCC.

For further details see:

Kura Oncology doses first patient in mid-stage tipifarnib + alpelisib study in head/neck cancer